IonOpticks expands its global reach and drives innovation with Adelis partnership. The company aims to better serve the growing demand for proteomics tools and deliver cutting-edge solutions to researchers worldwide.
 |
| Industry heavyweights join IonOpticks board as company partners with Adelis. The strategic partnership will enable IonOpticks to scale its operations, enhance product development, and strengthen its position in the proteomics market. Image Courtesy: IonOpticks |
Fitzroy, Australia– September 10, 2024:
IonOpticks, a renowned global producer of high-performance chromatography columns, has announced a strategic partnership with Adelis Equity Partners, a leading Nordic private equity firm. This collaboration aims to bolster IonOpticks' global presence and drive innovation in the rapidly growing field of proteomics.
The investment from Adelis will enable IonOpticks to expand its operations, enhance product development, and better serve its growing customer base. By establishing a stronger presence in key markets, IonOpticks will ensure that researchers worldwide can benefit from its cutting-edge chromatography solutions.
To support this growth, IonOpticks has strengthened its board with the appointment of several industry heavyweights, including Dr. Peter Wrighton-Smith as Chairman. With his extensive experience in scaling life sciences companies, Dr. Wrighton-Smith will provide invaluable guidance to IonOpticks as it enters its next phase of expansion.
The partnership with Adelis aligns perfectly with IonOpticks' vision for the future. Both companies share a commitment to innovation and a desire to make a significant impact in the field of human health. By combining IonOpticks' expertise in chromatography with Adelis' financial resources and industry knowledge, the partnership will accelerate the development of new solutions for proteomics research.
"We are thrilled to partner with Adelis," said Xavier Perronnet, Chief Executive Officer of IonOpticks. "Their support will enable us to continue pushing the boundaries of chromatography and deliver even more valuable tools to researchers around the world."
Adelis is equally excited about the partnership. "IonOpticks is a truly exceptional company with a bright future," said Rasmus Molander, Co-Managing Partner at Adelis. "We are confident that our investment will help them achieve their goals and make a lasting contribution to the field of proteomics."
The partnership between IonOpticks and Adelis is a testament to the growing importance of proteomics research and the potential of Australian life sciences innovations. As IonOpticks continues to expand its global footprint and develop new products, it is poised to become a leading player in the field of chromatography.